Background: In patients with early rheumatoid arthritis, initial com-bination therapies provide earlier clinical improvement and less pro-gression of joint damage after 1 year compared with initial mono-therapies (as demonstrated in the BeSt study). Objective: To evaluate whether the initial clinical and radiographic efficacy of combination therapies could be maintained during the second year of follow-up in patients with early rheumatoid arthritis. Design: Randomized, controlled clinical trial with blinded assessors. Setting: 18 peripheral and 2 university medical centers in the Neth-erlands. Patients: 508 patients with early active rheumatoid arthritis. Intervention: Sequential monotherapy (group 1), step-up combi-nation therapy (group 2)...
International audienceObjectives. In early and active RA despite MTX, continuous treatment with TNF ...
Objective To compare clinical and radiological outcomes of four dynamic treatment strategies in rece...
OBJECTIVES: Methotrexate (MTX), often combined with low moderately dosed prednisone, is still the co...
BACKGROUND: In patients with early rheumatoid arthritis, initial combination therapies provide earli...
Objective. Several treatment strategies have proven value in the amelioration of rheumatoid arthriti...
OBJECTIVE: To compare four different inception cohorts of patients with early rheumatoid arthritis (...
Item does not contain fulltextOBJECTIVE: To compare four different inception cohorts of patients wit...
Background: Early and intensive targeted treatment with disease modifying anti-rheumatic drugs (DMAR...
Objective-To compare four different inception cohorts of patients with early rheumatoid arthritis (R...
BACKGROUND: Treat to target (T2T) is widely accepted as the standard of care for patients with rheum...
Background: Treat to target (T2T) is widely accepted as the standard of care for patients with rheum...
Abstract Background Early and intensive targeted treatment with disease modifying anti-rheumatic dru...
Contains fulltext : 172822.pdf (publisher's version ) (Open Access)BACKGROUND: Tre...
Objectives To compare outcomes of targeted treatment aimed at either low disease activity or remissi...
Objectives To compare outcomes of targeted treatment aimed at either low disease activity or remissi...
International audienceObjectives. In early and active RA despite MTX, continuous treatment with TNF ...
Objective To compare clinical and radiological outcomes of four dynamic treatment strategies in rece...
OBJECTIVES: Methotrexate (MTX), often combined with low moderately dosed prednisone, is still the co...
BACKGROUND: In patients with early rheumatoid arthritis, initial combination therapies provide earli...
Objective. Several treatment strategies have proven value in the amelioration of rheumatoid arthriti...
OBJECTIVE: To compare four different inception cohorts of patients with early rheumatoid arthritis (...
Item does not contain fulltextOBJECTIVE: To compare four different inception cohorts of patients wit...
Background: Early and intensive targeted treatment with disease modifying anti-rheumatic drugs (DMAR...
Objective-To compare four different inception cohorts of patients with early rheumatoid arthritis (R...
BACKGROUND: Treat to target (T2T) is widely accepted as the standard of care for patients with rheum...
Background: Treat to target (T2T) is widely accepted as the standard of care for patients with rheum...
Abstract Background Early and intensive targeted treatment with disease modifying anti-rheumatic dru...
Contains fulltext : 172822.pdf (publisher's version ) (Open Access)BACKGROUND: Tre...
Objectives To compare outcomes of targeted treatment aimed at either low disease activity or remissi...
Objectives To compare outcomes of targeted treatment aimed at either low disease activity or remissi...
International audienceObjectives. In early and active RA despite MTX, continuous treatment with TNF ...
Objective To compare clinical and radiological outcomes of four dynamic treatment strategies in rece...
OBJECTIVES: Methotrexate (MTX), often combined with low moderately dosed prednisone, is still the co...